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Abstract 
Genome-wide association studies (GWAS) have proved to be a powerful approach for gene discovery 
in schizophrenia; their findings have profound implications not just for our understanding of the 
genetic architecture of the disorder, but for the potential applications of personalised medicine 
through targeted diagnosis and therapies. In this article we review the current status of GWAS 
literature in schizophrenia including functional annotation methods and polygenic risk scoring, as 
well as the directions and challenges of future research. We consider recent findings in East Asian 
populations and the advancements from trans-ancestry analysis, as well as the insights gained from 
research looking across psychiatric disorders.  
 
Introduction 
It has been well established through twin and family studies that schizophrenia has a strong genetic 
component, with heritability estimates of around 80-85% (Cardno and Gottesman, 2000). Prior to 
genome-wide association studies (GWAS), research relied on the use of candidate gene and linkage 
approaches to identify variants associated with the disorder. These methods proved largely 
unsuccessful for schizophrenia gene discovery, with prime targets such as DISC1 lacking replication 
within candidate studies and failing to gain support from subsequent GWAS (Mathieson et al., 2012; 
Sullivan, 2013). Advances in genotyping technology allowed the field to move away from such 
methods, enabling genome-wide data-driven approaches and the potential of identifying common 
variants of individually small effect that, when aggregated, increase predisposition to the disorder.  
Success in identifying common variants has largely been driven by falling costs of genotyping 
technology, allowing for efficient processing of much greater sample sizes (van Dijk et al., 2014). 
However, a sufficiently-powered GWAS in schizophrenia has been proven to require tens of 
thousands of cases (Sullivan et al., 2018), creating a challenge for individual groups. Hence 
international collaboration has been integral to the advances secured through GWAS, with research 
groups working as consortia to meta-analyse their data and reach the necessary sample sizes for 
high-powered discovery. The most notable and productive of these collaborations in the mental 
health field has been the Psychiatric Genomics Consortium (PGC), whose Schizophrenia Working 
Group spans researchers from hundreds of institutions worldwide (Sullivan et al., 2018). The joint 
efforts of this group have provided key advances in our understanding of the genetic underpinnings 
of schizophrenia. As we enter the third wave of the PGC (PGC3), greater sample sizes combined with 
in-depth phenotype data and advanced analytic strategies should further elucidate the genetic 
nature of schizophrenia.   
 
Current status of GWAS in schizophrenia 
Given the polygenic nature of schizophrenia, the vast majority of its common risk alleles will have 
small effect sizes, conferring genotype relative risks lower than 1.5 (Sullivan et al., 2012). This makes 
small sample sizes arguably the biggest factor hindering progress in schizophrenia genetics, as a 
certain threshold of cases and controls is required to achieve adequate  power to detect variants of 
small effect (Sullivan et al., 2018, 2012). Early schizophrenia GWAS failed to identify markers reaching 
genome-wide significance, primarily due to their lack of power, though when samples were combined 
genome-wide significant alleles were identified O Do o a  et al., ; Shi et al., ; Stefa sso  
et al., 2009; Sullivan et al., 2008). The last decade has seen large-scale international collaboration 
enabling us to move from the first studies that identified one genome-wide significant locus for 
psychosis in just 479 cases O Do o a  et al., , to the amalgamation of datasets containing 
upward of 40,000 cases identifying 145 significant loci (Pardiñas et al., 2018). Early partnerships 
between the International Schizophrenia Consortium (ISC), Molecular Genetics of Schizophrenia 
(MGS), and SGENE groups unearthed the first major findings of common variants in the major 
histocompatibility complex (MHC), as well as markers in TCF4 and NRGN, implicating dysfunctional 
brain development and cognitive functioning as key pathophysiological processes of potential 
relevance in schizophrenia (Stefansson et al., 2009). These landmark findings illustrated the polygenic 
nature of schizophrenia, whilst demonstrating the necessity for international collaboration to amass 
large samples and thus facilitate reliable genomic discovery efforts.  Other collaborations have since 
supported and expanded upon these findings, with the first wave of PGC schizophrenia data (PGC1) 
identifying single nucleotide polymorphisms (SNPs) across seven loci in a total combined sample of 
17,836 cases and 33,859 controls (The Schizophrenia Psychiatric Genome-Wide Association Study 
(GWAS) Consortium, 2011). The data from this study was combined with additional samples, mainly 
from a large Swedish case control cohort, in a meta-analysis with total sample size 21,246 cases and 
38,072 controls, and identified 22 loci, 13 of which were novel associations (Ripke et al., 2013). In 
these initial schizophrenia GWAS consortia studies one of the most consistent findings was strong 
support for association for the Major Histocompatibility Complex (MHC) region on chromosome 6, 
although identifying specific causal variants at this locus has been challenging due to the size, 
complexity, and high linkage disequilibrium (LD) of the region (Irish Schizophrenia Consortium and the 
Wellcome Trust Case Control Consortium 2, 2012; Lehner, 2012).   
Arguably the most ground-breaking discovery in schizophrenia genetics came from the second wave 
of data from the PGC schizophrenia working group (PGC2). A total of 34,241 cases and 45,604 controls 
were analysed, which, together with 1,235 parent-offspring samples and a replication sample of 1,513 
cases and 66,236 controls, led to the identification of 128 genome-wide significant SNPs, spanning 108 
independent loci, associated with schizophrenia (Schizophrenia Working Group of the Psychiatric 
Genomics Consortium, 2014). As well as a further demonstration of the importance of technological 
and analytic advances, the PGC2 study identified multiple novel candidate genes and pathways of 
potential therapeutic relevance. For the first time the PGC2 study found genome-wide significant 
association with a polymorphism implicating the DRD2 gene, encoding the Dopamine D2 receptor, 
which is the therapeutic target of all currently licensed antipsychotic medications, thus providing a 
validation of the GWAS approach in schizophrenia. Moreover, the group reported 82 novel 
associations, including SNPs implicating genes enriched for glutamatergic neurotransmission and 
synaptic plasticity.  Building on this work with the addition of new schizophrenia samples in the 
CLOZUK sample, Pardiñas and colleagues extended the PGC2 findings using up-to-date gene set 
analyses to demonstrate an enrichment of variants in genes that are intolerant to rare loss-of-function 
mutations, as well as in gene sets involved in synaptic and neuronal functioning and also highlighted 
the strong enrichment of SNPs in regions under strong background selection (Pardiñas et al., 2018).  
Despite the many successes of these studies, GWAS have so far been unable to explain the majority 
of schizophrenia heritability, with only 22.5% of variance currently explained in common variant 
studies and much less in rare variant analyses (Pardiñas et al., 2018). Missing heritability poses a 
significant challenge to future research, which may in part be overcome through further study of rare 
variants, environmental modifiers, and epigenetic effects (Eichler et al., 2010; Manolio et al., 2009). 
Furthermore, schizophrenia GWAS have predominantly been undertaken in populations of European 
ancestry. Restricting a sample to individuals of the same ancestry allows better control of population 
stratification, thereby limiting the rate of false positives arising from systematic differences between 
cases and controls (Wu et al., 2011). However, meta-analysis of ancestry-specific results can 
successfully address confounding effects (Wang et al., 2013), indicating that  excluding non-European 
samples from studies limits our ability to generalise GWAS results and underestimates the genetic 
burden carried by individuals in these populations (Martin et al., 2017). As an example, polygenic risk 
scores (PRS) calculated from a European population explained substantially less of the variance in an 
African-American sample compared to two independent European samples (The International 
Schizophrenia Consortium, 2009). The evolutionary history of the human species and its rapid 
demographic expansion makes it likely that some degree of population-specific risk exists, and by 
limiting ourselves to one population we are potentially missing important contributors to 
schizophrenia heritability. More substantial GWAS in Asian populations have gradually emerged over 
the past decade, with discovery sample sizes progressing from less than a thousand cases in some of 
the earliest studies (Ikeda et al., 2011; Yue et al., 2011) to over 13,000 in the most recent PGC analysis 
(Lam et al., 2018). The findings from schizophrenia GWAS in Asian populations have been broadly 
consistent with those of European populations (Yue et al., 2017). A recent study meta-analysed results 
from 8723 cases of Han Chinese ancestry and found associations at three loci, all of which had 
previously been found in European samples (Yu et al., 2017). Research by Li et al. (2017) found seven 
genome-wide significant loci in an analysis of those with Chinese ancestry, three of which had 
previously been found in schizophrenia GWAS restricted to those of European ancestry. The remaining 
four loci were only associated with schizophrenia in the Chinese sample and were not significant in a 
trans-ancestry analysis with PGC2 data. Additionally, they found 26 novel loci amongst 106 significant 
loci through trans-ancestry analysis, owing to the greater power of the larger combined sample. 
Notably, GWAS of Asian populations often fail to find associations in the MHC (Corvin and Morris, 
2014; Lam et al., 2018), despite strong evidence in European populations. It has been suggested that 
this may be due to ancestry-specific patterns of LD combined with higher minor allele frequency (MAF) 
of key SNPs in this region in European samples compared to Asian samples (Lam et al., 2018), 
resembling observations in some immune phenotypes (Matzaraki et al., 2017).  
Sampling different ancestries can provide insights into SNPs with MAF that are too rare to be studied 
in any single population. In a sample of Han Chinese ancestry, Yu et al. (2017) identified a significant 
SNP within the GABBR1 gene with a MAF of 0.13 in an Asian sample, compared to 0.01 a European 
sample. Dysfunction in the GABA system has been implicated in schizophrenia (Wassef et al., 2003), 
suggesting that variation within this gene could play a role in both European and Asian populations.  
In recent work by the PGC, 21 variants spanning 19 loci were found to be significant in an East Asian 
sample (Lam et al., 2018). Of these, 15 loci had a higher MAF in the Asian sample compared to 
European samples. The locus containing CACNA2D2 was significant in the Asian sample only, likely 
owing to vastly different MAF in the index SNP; 45% in Asian and 0.07% in European samples, 
respectively. The association with this variant suggests that whilst different patterns of LD and MAF 
may implicate different causal SNPs and/or haplotypes, the underlying genes and pathways implicated 
are shared across populations. Consistent with this idea is the finding of a genetic correlation of 0.98 
between European and Asian samples, indicating that the genetic architecture of schizophrenia is 
largely consistent across populations (Lam et al., 2018). The study s fi di gs o fir  that, in the 
particular case of schizophrenia, meta-analysing samples of different ancestries is not only a valid 
approach but is advantageous compared to analyses restricted to ancestrally-homogenous samples. 
 
Fine-mapping and functional annotation 
With increasing sample sizes, as well as technical developments such as improved imputation, many 
more associated loci have been identified by schizophrenia GWAS. In order to move from these 
implicated genomic regions of association to identifying putatively causal variants and genes 
(Zondervan and Cardon, 2004), statistical fine-mapping and functional annotation techniques have 
been developed and implemented in recent years. Statistical fine-mapping is a commonly used 
technique that aims to overcome this problem by assigning each candidate variant a probability of 
being the causal variant at that locus (Spain and Barrett, 2015). High LD in many associated regions 
complicates this process, but again the use of data from multiple ancestries is starting to overcome 
this issue by exploiting the differences in patterns of LD between populations. Li et al. (2017) found 
that 80% of SNP sets spanned smaller regions when using trans-ancestry data compared to European 
or Chinese samples alone. Of 62 variants reaching the threshold for high causal probability, 38 had a 
higher probability in trans-ancestry analyses, including 16 that did not reach the threshold in single-
ancestry analysis. In trans-ancestry work by the PGC, the number of credible SNPs was refined in 93 
loci, 20 loci were associated with a single variant, compared to 16 in previous work, an additional 
seven loci were refined to less than five candidate variants, and the overall median size of the mapped 
loci was reduced by over half (Lam et al., 2018).   
Functional annotation of significant variants allows for analysis across pathways and gene sets, 
marking an important next step toward understanding the biological role of these variants. 
Additionally, grouping SNPs by function may better identify SNPs and genes to create an easier target 
for therapy development in the near future O Do o a  a d O e , . Pardiñas et al. (2018) 
assessed central nervous system-related gene sets and found six associated with schizophrenia, 
including targets of Fragile X mental retardation protein (FMRP), voltage-gated calcium ion channel 
complexes, and abnormal long-term potentiation. Voltage-gated calcium ion channels have been 
robustly implicated in schizophrenia, GWAS and gene set analysis reporting associations in European 
and Asian populations (Green et al., 2010; Jiang et al., 2015; Li et al., 2017; Ripke et al., 2013). 
Furthermore, variants in this gene set have been consistently implicated in other psychiatric disorders, 
notably bipolar disorder, suggesting a mechanism through which phenotypic and genotypic overlap 
may occur (Ferreira et al., 2008; Psychiatric GWAS Consortium Bipolar Disorder Working Group., 
2011). The findings of Pardiñas et al. (2018) provide evidence of a potential shared aetiology with 
autism spectrum disorders, which have also been associated with variation in FMRP and its targets 
(Iossifov et al., 2012; Steinberg and Webber, 2013). Schizophrenia and autism are known to share both 
common and rare genetic risk (Carroll and Owen, 2009; Cross-Disorder Group of the Psychiatric 
Genomics Consortium, 2019) and more detailed exploration of SNPs within the FMRP gene set may 
further elucidate their common and pleiotropic effects.  
Gene sets implicated by common variant studies overlap with those discovered through CNV and 
rare variant analyses. De novo mutations have been shown to be enriched in genes involved in 
calcium ion channels, synaptic plasticity, and FMRP targets (Fromer et al., 2014; Purcell et al., 2014). 
However, several studies report an enrichment of rare mutations in ARC and NMDAR gene sets 
(Fromer et al., 2014; Kirov et al., 2012; Pocklington et al., 2015; Purcell et al., 2014), which has not 
been reported robustly in common variant analysis. It remains possible that sampling of non-
European populations may reveal common variants in these pathways that are too rare to detect 
within European populations. 
The gene sets discussed provide evidence that risk variants for schizophrenia act by disrupting the 
functioning of the synapse through multiple inter-related mechanisms (Hall et al., 2015; Owen, 
2012). Analysis of transcriptomic data in PGC2 provides further support for this hypothesis by 
demonstrating that common variants identified are enriched for expression in the brain, and not in 
tissues thought to be unrelated to schizophrenia (Schizophrenia Working Group of the Psychiatric 
Genomics Consortium, 2014). Further analyses also found an enrichment of variants expressed in 
tissues and pathways associated with immune function, suggesting a role of immunity in 
schizophrenia (The Network and Pathway Analysis Subgroup of the Psychiatric Genomics 
Consortium, 2015). While this might not necessarily implicate large numbers of immune genes 
(Pouget, 2018), consistent findings in the MHC do support this hypothesis, with variation in 
complement component 4 (C4) in particular showing strong evidence of association with 
schizophrenia (Sekar et al., 2016). In addition to the above fine mapping and functional gene set 
annotations, which rely on LD and genomic location, functional annotation is also possible using 
experimentally derived data. These include expression quantitative trait locus data (eQTL), 
methylomic and open chromatin data, and functional data derived from the 3D conformation of 
chromatin, such as Hi-C. Such approaches have been investigated in schizophrenia (Huckins et al., 
2019; Pardiñas et al., 2018)and are described elsewhere in this special issue. 
Application of GWAS results 
Polygenic risk scoring has rapidly emerged as a powerful and potentially clinically useful application of 
GWAS results. SNPs identified through GWAS as being significant at a given threshold are weighted by 
their association odds ratios and summed for each individual to create a risk score in an independent 
dataset, with higher scores indicating greater genetic liability to the disorder. The ISC (2009) were the 
first to use this method to predict schizophrenia case-control status, finding that schizophrenia PRS 
was a highly significant predictor of the disorder in European samples. Moreover, schizophrenia PRS 
significantly predicted bipolar disorder case status, adding further weight to evidence from GWAS that 
the two disorders share a common genetic architecture, which was later further quantified through 
genetic correlation (rg=0.70) (Cross-Disorder Group of the Psychiatric Genomics Consortium, 2019, 
2013). Such powerful genetic prediction has the potential to be clinically useful although the situations 
in which such information may be clinically employed require careful consideration including the 
limitations in the application of PRS across populations (Martin et al., 2019) and hence there is an 
ongoing debate about whether PRS can safely and effectively be implemented in medical genetic 
settings (Torkamani et al., 2018). At the moment, PRS is only weakly able to predict schizophrenia 
status, with an area under the curve (AUC) of 0.65 (Ripke et al., 2013). Consequently, current scores 
are unreliable for diagnostic purposes, though they have showed some encouraging performance in 
first-episode psychosis samples (Vassos et al., 2017). For research purposes, however, some study 
designs might benefit from sampling cases at the extreme of the PRS distribution, in a manner similar 
to CNV studies that compare deletion with duplication cases (Niarchou et al., 2019). Power of this 
design depends on the difference between the risk profiles of the two studied groups (Risch and 
Zhang, 1995), which is related, but not analogous, to the predictive accuracy of the risk factor that has 
been used to select them (Wald et al., 1999). To illustrate this point, a recent study assessed the 
CLOZUK sample, a UK-wide study of 11,260 schizophrenia cases and 24,542 controls (Pardiñas et al., 
2018). PRS analysis of CLOZUK showed an AUC=0.67 to predict schizophrenia case status, with a 5.7% 
variance explained, values similar to most PGC2 cohorts. In presenting previously unpublished data 
we show that when CLOZUK case control sample was stratified into PRS percentiles, the difference 
et ee  the top a d the otto  per e tile o ferred a  O‘≈  Figure 1), larger than that conferred 
by several highly penetrant CNVs (Rees et al., 2014). This shows that PRS might be an effective way of 
screening and prioritising population samples for functional and post-GWAS studies. 
Increasing sample sizes and diversity can also improve PRS-based prediction, with Li et al. (2017) 
reporting up to 8% of variance in schizophrenia status within their sample explained by PRS derived 
from the PGC2 plus the Chinese ancestry data, an improvement of 5% from PGC2 alone. Although 
these improvements are relatively small, they indicate that missing heritability may in part be 
explained by the under-representation of non-European populations within GWAS cohorts. Further 
sampling of individuals from multiple ancestries will improve schizophrenia prediction across 
worldwide populations.  
Given the explanatory power of PRS for susceptibility to schizophrenia, studies have investigated 
whether these scores can be informative regarding clinical heterogeneity within the disorder.  
Chronicity of illness, indexed by number and length of hospital admissions, is associated with 
schizophrenia PRS (Meier et al., 2016). Conversely, treatment-resistance to medication does not 
appear to be predicted by PRS, despite being associated with number of hospitalisations (Legge et al., 
in press; Martin and Mowry, 2016; Wimberley et al., 2017). These findings suggest a complex 
relationship between polygenic risk scores and outcomes which is in part dependent on the 
constitution of the schizophrenia training dataset used for the polygenic risk score derivation (i.e. the 
mixture of poor and good outcome cases). Attempts to predict cognitive ability have also provided 
conflicting results, with schizophrenia PRS significantly predicting cognition in healthy adults and 
children but not in schizophrenia cases (Germine et al., 2016; Shafee et al., 2018). Limited research 
has currently been conducted on genetic influences of specific symptoms in schizophrenia, with 
available evidence indicating that schizophrenia PRS predicts symptoms within a 
negative/disorganised domain, but not positive psychotic symptoms (Fanous et al., 2012). Consistent 
with this are findings that schizophrenia PRS does not predict psychotic experiences in adolescence 
but in contrast does predict negative symptoms at age 16 (Jones et al., 2016). These associations 
suggest that genetic liability for schizophrenia may manifest as negative symptoms (Mistry et al., 
2018), and that further exploration of positive symptoms is required in order to understand the 
aetiology of this phenotype.  
 
Cross-disorder risk 
The validity of existing diagnostic categories for psychotic and mood disorders has often been 
questioned (Allardyce et al., 2007), particularly given the evidence of a spectrum of illness and the 
existence of intermediary categories that fit neatly on neither side of the dichotomy, such as 
schizoaffective disorder bipolar subtype. Subsequently, additional insights have been gained by cross 
disorder analyses, particularly between schizophrenia and bipolar disorder. Several studies have 
employed this method, with the most recent findings identifying 32 loci associated with schizophrenia 
and bipolar disorder and eight significant pathways, of which seven are involved in synaptic and 
neuronal functioning (Ruderfer et al., 2018). These findings suggest that disrupted neuronal signalling 
plays a key role across both disorders, and is consistent with previous findings within each disorder 
(Nurnberger et al., 2014; Schizophrenia Working Group of the Psychiatric Genomics Consortium, 
2014). The cross-disorder group of the PGC has looked across eight psychiatric disorders, including 
schizophrenia and bipolar disorder, to identify pleiotropic loci and their role in shared aetiology. They 
found 136 loci reaching genome-wide significance, including 23 associated with at least four disorders. 
Consistent with pleiotropic effects, significant SNPs were enriched for genes known to be expressed 
in multiple brain tissues. One SNP, located in the gene DCC, was associated with all eight disorders 
and is involved in axonal growth during prenatal development. Gene set analysis implicated 
neurogenesis and neuron differentiation, as well as synaptic signalling sets, including voltage gated 
calcium channels. Eleven loci were shown to have opposite effects on risk between disorders, 
including two with opposite effects on schizophrenia and ASD. Notably, no loci had opposite effects 
on schizophrenia and bipolar disorder (Cross-Disorder Group of the Psychiatric Genomics Consortium, 
2019).  
Other research has utilised PRS and genetic correlation analyses to measure the overlap between 
psychiatric disorders. Allardyce et al. (2018) report schizophrenia PRS predicting bipolar sub-types 
along a spectrum, with the strongest prediction for schizoaffective bipolar and the weakest for bipolar 
II disorder. Furthermore, individuals with Bipolar I disorder and psychosis showed greater enrichment 
of schizophrenia PRS than individuals with bipolar I disorder who had not experienced psychosis, 
suggesting that schizophrenia PRS may predict more severe illness course in bipolar disorder.  The 
findings demonstrate that genetic overlap between schizophrenia and bipolar disorder can be seen at 
a phenotypic level, and provide further weight to the suggestion of a spectrum of psychotic illness that 
includes bipolar disorder as has been shown in studies of cognition Ly ha  et al., ; O Do o a  
and Owen, 2016). Research by the Brainstorm Consortium measured genetic correlations between 25 
neurological and psychiatric disorders, as well as several behavioural and cognitive phenotypes. They 
found positive associations between schizophrenia and most other psychiatric disorders, as well as 
with years in education and neuroticism. Significant negative associations were observed between 
schizophrenia and intelligence, subjective well-being, and BMI (The Brainstorm Consortium, 2018). 
The authors suggest this may reflect a general psychopathology factor on which other genetic and 
environmental factors influence illness presentation, as previously proposed (Caspi et al., 2014). 
Alternatively, it may also be due to endophenotypes or symptom dimensions that traverse disorders. 
Whatever the explanation these results indicate the complexity of cross disorder relationships and the 
heterogeneity of schizophrenia, but also highlight the fact that cross disorder analytic approaches may 
offer insights into aetiology and classification of schizophrenia and related disorders.  
 
Future directions 
Over the past decade our understanding of the genetic architecture of schizophrenia, and the nature 
of the condition itself, has developed substantially due to large genomic studies made possible by 
technological advances and internal collaboration. A picture has emerged of a complex polygenic 
disorder, with over 150 common genetic loci associated with the disorder implicating synaptic protein 
dysfunction and disruption of neurodevelopment and function. Moreover, we now know that these 
common variants are enriched in loss of function-intolerant genes, suggesting that schizophrenia in 
part arises from an excess burden of deleterious variation in highly conserved regions that underpin 
important biological functions. We also know the prevalence of common risk variants in the 
population is not necessarily due to ancient advantageous effects (Keller, 2018), but that the 
persistence of mildly deleterious common variants is made possible through the evolutionary 
processes of background selection and genetic drift, which recurrently remove mutations of large 
deleterious effect, allowing  those of small effect to rise in frequency (Pardiñas et al., 2018).  
Despite these substantial advances, many challenges still face the field of schizophrenia genomics. 
Whilst sample sizes in schizophrenia are increasing, they remain substantially smaller than GWAS of 
non-psychiatric illnesses and phenotypes such as blood pressure and educational attainment, which 
have combined discovery and replication sample sizes of over 750,000 and 1 million, respectively (Giri 
et al., 2019; Lee et al., 2018). The availability of large population-based cohorts, such as UK Biobank 
and 23andMe, is unlikely to address this problem, as they show low rates of participation for severe 
psychiatric conditions and those that do participate in such studies are poorly representative of those 
with the condition under clinical care (Kendall et al., 2017). The PGC is making considerable strides in 
enhancing recruitment in this area, with ongoing waves of data aiming to recruit over 100,000 cases 
using novel high throughput recruitment strategies which have been shown to be effective (Pardiñas 
et al., 2018). A sample of this size will allow for greater predictive accuracy of PRS, which may be used 
to assess environmental interactions, phenotypic relationships, and developmental effects (Sullivan 
et al., 2018). Moreover, the sample can be used to measure genetic correlations across psychiatric 
and neurological disorders, as well as assess potential causation through methods such as Mendelian 
randomisation (Sullivan et al., 2018). 
Furthermore, we are limited in our ability to assign causal SNPs at each identified locus, with recent 
work identifying only 27 confidently assigned causal SNPs out of a possible 145 genome-wide 
significant loci (Pardiñas et al., 2018), a result which is consistent with other complex disorders 
assessed using related methods (Huang et al., 2017). The use of trans-ancestry data is beginning to 
improve our ability to fine-map associated loci (Lam et al., 2018), therefore future research will need 
to sample individuals from diverse backgrounds in order to identify the causal SNPs. GWAS of Asian 
populations are becoming more prominent in the literature, yet African ancestries still remain vastly 
under-represented. Sampling a diverse range of ancestries will also aid our ability to detect rarer 
variants, as well as address a major barrier to any clinical application of polygenic risk score prediction, 
alongside advances in imputation panels allowing variants with much smaller MAF to be imputed and 
tested (Corvin and Sullivan, 2016). 
Other work by the PGC and other groups is utilising GWAS to further our understanding of the clinical 
dimensions of schizophrenia. By analysing genetic risk at a symptom or endophenotype level, the issue 
of clinical heterogeneity may be addressed leading to improvements in classification based more on 
aetiology than symptomatic presentation. However, advances of this type will be reliant on the 
availability of deep phenotype data at scale and will require significant investment of research 
resources to produce replicable findings alongside renewed investment in international collaboration. 
Data linkage to anonymised electronic health records may help to facilitate this process by providing 
a wealth of longitudinal data that cannot be achieved accurately through participant interview. For 
instance, use of the Danish National Registry has produced research showing associations between 
increased risk of schizophrenia and both maternal C-reactive protein and maternal exposure to stress 
during pregnancy (Canetta et al., 2014; Khashan et al., 2008). Further advancements in genomic 
technologies also present a challenge to future schizophrenia GWAS research. Whilst next-generation 
sequencing technology is advancing rapidly and costs are falling, the regulatory environment is 
changing and secure storage and access to this data remains a challenge. Similarly whilst international 
efforts are underway to realise the potential of electronic health data, streamlined linkage of genomic 
data to these datasets is far from simple even in well-funded research fields such as oncology 
(Agarwala et al., 2018). As we move toward whole-genome sequencing in much larger samples, these 
issues will only become more apparent hence equivalent advances are required in study design, 
regulatory environments and funding streams to fully realise the potential of this data.  
Overall, the past decade has seen tremendous progress in our ability to rapidly analyse tens of 
thousands of samples and identify common loci contributing to risk of developing schizophrenia. 
These loci cluster in genes with important neurological functions, with many contributing not just to 
schizophrenia, but also to a host of related neuropsychiatric conditions and traits. GWAS have led to 
the development of a number of experimental analyses that aim to determine through which variants 
and genes these loci act to confer risk of schizophrenia, to elucidate the actions of such variants across 
disorders, and their potential use in predicting outcomes in patients. Continued investment in GWAS 
seems warranted given the insights they have provided that have established GWAS as a valid, 
valuable and widely employed methodology. Ongoing collaboration and the engagement and support 
of patients is crucial in order to continue to build the required sample sizes that are needed to fully 
realise the clinical potential of GWAS findings.  
 
References 
Agar ala, V., Khozi , S., Si gal, G., O Co ell, C., Kuk, D., Li, G., Gossai, A., Miller, V., A er ethy, A.P., 
2018. Real-World Evidence In Support Of Precision Medicine: Clinico-Genomic Cancer Data As A 
Case Study. Health Aff. 37, 765–772. https://doi.org/10.1377/hlthaff.2017.1579 
Allardyce, J., Gaebel, W., Zielasek, J., van Os, J., 2007. Deconstructing Psychosis Conference February 
2006: The Validity of Schizophrenia and Alternative Approaches to the Classification of 
Psychosis. Schizophr. Bull. 33, 863–867. https://doi.org/10.1093/schbul/sbm051 
Allardyce, J., Leonenko, G., Hamshere, M., Pardiñas, A.F., Forty, L., Knott, S., Gordon-Smith, K., 
Porteous, D.J., Haywood, C., Di Florio, A., Jones, L., McIntosh, A.M., Owen, M.J., Holmans, P., 
Walters, J.T.‘., Craddo k, N., Jo es, I., O Do o a , M.C., Es ott-Price, V., 2018. Association 
Between Schizophrenia-Related Polygenic Liability and the Occurrence and Level of Mood-
Incongruent Psychotic Symptoms in Bipolar Disorder. JAMA Psychiatry 75, 28. 
https://doi.org/10.1001/jamapsychiatry.2017.3485 
Canetta, S., Sourander, A., Surcel, H.-M., Hinkka-Yli-Salomäki, S., Leiviskä, J., Kellendonk, C., 
McKeague, I.W., Brown, A.S., 2014. Elevated Maternal C-Reactive Protein and Increased Risk of 
Schizophrenia in a National Birth Cohort. Am. J. Psychiatry 171, 960–968. 
https://doi.org/10.1176/appi.ajp.2014.13121579 
Cardno, A.G., Gottesman, I.I., 2000. Twin studies of schizophrenia: From bow-and-arrow 
concordances to Star Wars Mx and functional genomics. Am. J. Med. Genet. 97, 12–17. 
https://doi.org/10.1002/(SICI)1096-8628(200021)97:1<12::AID-AJMG3>3.0.CO;2-U 
Carroll, L.S., Owen, M.J., 2009. Genetic overlap between autism, schizophrenia and bipolar disorder. 
Genome Med. 1, 102. 
Caspi, A., Houts, R.M., Belsky, D.W., Goldman-Mellor, S.J., Harrington, H., Israel, S., Meier, M.H., 
Ramrakha, S., Shalev, I., Poulton, R., Moffitt, T.E., 2014. The p Factor. Clin. Psychol. Sci. 2, 119–
137. https://doi.org/10.1177/2167702613497473 
Corvin, A., Morris, D.W., 2014. Genome-wide Association Studies: Findings at the Major 
Histocompatibility Complex Locus in Psychosis. Biol. Psychiatry 75, 276–283. 
https://doi.org/10.1016/J.BIOPSYCH.2013.09.018 
Corvin, A., Sullivan, P.F., 2016. What Next in Schizophrenia Genetics for the Psychiatric Genomics 
Consortium? Schizophr. Bull. 42, 538–541. https://doi.org/10.1093/schbul/sbw014 
Cross-Disorder Group of the Psychiatric Genomics Consortium, 2019. Genome wide meta-analysis 
identifies genomic relationships, novel loci, and pleiotropic mechanisms across eight psychiatric 
disorders. bioRxiv 528117. https://doi.org/10.1101/528117 
Cross-Disorder Group of the Psychiatric Genomics Consortium, 2013. Identification of risk loci with 
shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet 381, 1371–
1379. https://doi.org/10.1016/S0140-6736(12)62129-1 
Eichler, E.E., Flint, J., Gibson, G., Kong, A., Leal, S.M., Moore, J.H., Nadeau, J.H., 2010. Missing 
heritability and strategies for finding the underlying causes of complex disease. Nat. Rev. 
Genet. 11, 446–450. https://doi.org/10.1038/nrg2809 
Fanous, A.H., Zhou, B., Aggen, S.H., Bergen, S.E., Amdur, R.L., Duan, J., Sanders, A.R., Shi, J., Mowry, 
B.J., Olincy, A., Amin, F., Cloninger, C.R., Silverman, J.M., Buccola, N.G., Byerley, W.F., Black, 
D.W., Freedman, R., Dudbridge, F., Holmans, P.A., Ripke, S., Gejman, P. V., Kendler, K.S., 
Levinson, D.F., Levinson, D.F., 2012. Genome-Wide Association Study of Clinical Dimensions of 
Schizophrenia: Polygenic Effect on Disorganized Symptoms. Am. J. Psychiatry 169, 1309–1317. 
https://doi.org/10.1176/appi.ajp.2012.12020218 
Ferreira, M.A.‘., O Do o a , M.C., Me g, Y.A., Jo es, I.‘., ‘uderfer, D.M., Jo es, L., Fa , J., Kiro , G., 
Perlis, R.H., Green, E.K., Smoller, J.W., Grozeva, D., Stone, J., Nikolov, I., Chambert, K., 
Hamshere, M.L., Nimgaonkar, V.L., Moskvina, V., Thase, M.E., Caesar, S., Sachs, G.S., Franklin, 
J., Gordon-Smith, K., Ardlie, K.G., Gabriel, S.B., Fraser, C., Blumenstiel, B., Defelice, M., Breen, 
G., Gill, M., Morris, D.W., Elkin, A., Muir, W.J., McGhee, K.A., Williamson, R., MacIntyre, D.J., 
MacLean, A.W., St Clair, D., Robinson, M., Van Beck, M., Pereira, A.C.P., Kandaswamy, R., 
McQuillin, A., Collier, D.A., Bass, N.J., Young, A.H., Lawrence, J., Nicol Ferrier, I., Anjorin, A., 
Farmer, A., Curtis, D., Scolnick, E.M., McGuffin, P., Daly, M.J., Corvin, A.P., Holmans, P.A., 
Blackwood, D.H., Gurling, H.M., Owen, M.J., Purcell, S.M., Sklar, P., Craddock, N., Craddock, N., 
2008. Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C 
in bipolar disorder. Nat. Genet. 40, 1056–1058. https://doi.org/10.1038/ng.209 
Fromer, M., Pocklington, A.J., Kavanagh, D.H., Williams, H.J., Dwyer, S., Gormley, P., Georgieva, L., 
Rees, E., Palta, P., Ruderfer, D.M., Carrera, N., Humphreys, I., Johnson, J.S., Roussos, P., Barker, 
D.D., Banks, E., Milanova, V., Grant, S.G., Hannon, E., Rose, S.A., Chambert, K., Mahajan, M., 
Scolnick, E.M., Moran, J.L., Kirov, G., Palotie, A., McCarroll, S.A., Holmans, P., Sklar, P., Owen, 
M.J., Pur ell, S.M., O Do o a , M.C., . De o o utatio s i  s hizophre ia i pli ate 
synaptic networks. Nature 506, 179–184. https://doi.org/10.1038/nature12929 
Germine, L., Robinson, E.B., Smoller, J.W., Calkins, M.E., Moore, T.M., Hakonarson, H., Daly, M.J., 
Lee, P.H., Holmes, A.J., Buckner, R.L., Gur, R.C., Gur, R.E., 2016. Association between polygenic 
risk for schizophrenia, neurocognition and social cognition across development. Transl. 
Psychiatry 6, e924–e924. https://doi.org/10.1038/tp.2016.147 
Giri, A., Hellwege, J.N., Keaton, J.M., Park, J., Qiu, C., Warren, H.R., Torstenson, E.S., Kovesdy, C.P., 
Sun, Y. V., Wilson, O.D., Robinson-Cohen, C., Roumie, C.L., Chung, C.P., Birdwell, K.A., 
Damrauer, S.M., DuVall, S.L., Klarin, D., Cho, K., Wang, Y., Evangelou, E., Cabrera, C.P., Wain, L. 
V., Shrestha, R., Mautz, B.S., Akwo, E.A., Sargurupremraj, M., Debette, S., Boehnke, M., Scott, 
L.J., Luan, J., Zhao, J.-H., Willems, S.M., Thériault, S., Shah, N., Oldmeadow, C., Almgren, P., Li-
Gao, R., Verweij, N., Boutin, T.S., Mangino, M., Ntalla, I., Feofanova, E., Surendran, P., Cook, 
J.P., Karthikeyan, S., Lahrouchi, N., Liu, C., Sepúlveda, N., Richardson, T.G., Kraja, A., Amouyel, 
P., Farrall, M., Poulter, N.R., Laakso, M., Zeggini, E., Sever, P., Scott, R.A., Langenberg, C., 
Wareham, N.J., Conen, D., Palmer, C.N.A., Attia, J., Chasman, D.I., Ridker, P.M., Melander, O., 
Mook-Kanamori, D.O., Harst, P. van der, Cucca, F., Schlessinger, D., Hayward, C., Spector, T.D., 
Jarvelin, M.-R., Hennig, B.J., Timpson, N.J., Wei, W.-Q., Smith, J.C., Xu, Y., Matheny, M.E., Siew, 
E.E., Lindgren, C., Herzig, K.-H., Dedoussis, G., Denny, J.C., Psaty, B.M., Howson, J.M.M., 
Munroe, P.B., Newton-Cheh, C., Caulfield, M.J., Elliott, P., Gaziano, J.M., Concato, J., Wilson, 
P.W.F., Tsao, P.S., Velez Ed ards, D.‘., Susztak, K., O Do ell, C.J., Hu g, A.M., Ed ards, T.L., 
2019. Trans-ethnic association study of blood pressure determinants in over 750,000 
individuals. Nat. Genet. 51, 51–62. https://doi.org/10.1038/s41588-018-0303-9 
Green, E.K., Grozeva, D., Jones, I., Jones, L., Kirov, G., Caesar, S., Gordon-Smith, K., Fraser, C., Forty, 
L., Russell, E., Hamshere, M.L., Moskvina, V., Nikolov, I., Farmer, A., McGuffin, P., Holmans, 
P.A., O e , M.J., O Do o a , M.C., Craddo k, N., 2010. The bipolar disorder risk allele at 
CACNA1C also confers risk of recurrent major depression and of schizophrenia. Mol. Psychiatry 
15, 1016–1022. https://doi.org/10.1038/mp.2009.49 
Hall, J., Tre t, S., Tho as, K.L., O Do o a , M.C., O e , M.J., 2015. Genetic Risk for Schizophrenia: 
Convergence on Synaptic Pathways Involved in Plasticity. Biol. Psychiatry 77, 52–58. 
https://doi.org/10.1016/J.BIOPSYCH.2014.07.011 
Hua g, H., Fa g, M., Josti s, L., U iće ić Mirko , M., Bou her, G., A derso , C.A., Andersen, V., 
Cley e , I., Cortes, A., Cri s, F., D A ato, M., Deffo tai e, V., D itrie a, J., Do a po, E., 
Elansary, M., Farh, K.K.-H., Franke, A., Gori, A.-S., Goyette, P., Halfvarson, J., Haritunians, T., 
Knight, J., Lawrance, I.C., Lees, C.W., Louis, E., Mariman, R., Meuwissen, T., Mni, M., 
Momozawa, Y., Parkes, M., Spain, S.L., Théâtre, E., Trynka, G., Satsangi, J., van Sommeren, S., 
Vermeire, S., Xavier, R.J., Weersma, R.K., Duerr, R.H., Mathew, C.G., Rioux, J.D., McGovern, 
D.P.B., Cho, J.H., Georges, M., Daly, M.J., Barrett, J.C., Barrett, J.C., 2017. Fine-mapping 
inflammatory bowel disease loci to single-variant resolution. Nature 547, 173–178. 
https://doi.org/10.1038/nature22969 
Huckins, L.M., Dobbyn, A., Ruderfer, D.M., Hoffman, G., Wang, W., Pardiñas, A.F., Rajagopal, V.M., 
Als, T.D., T. Nguyen, H., Girdhar, K., Boocock, J., Roussos, P., Fromer, M., Kramer, R., Domenici, 
E., Ga azo , E.‘., Pur ell, S., De o tis, D., Børglu , A.D., Walters, J.T.‘., O Do o a , M.C., 
Sullivan, P., Owen, M.J., Devlin, B., Sieberts, S.K., Cox, N.J., Im, H.K., Sklar, P., Stahl, E.A., 2019. 
Gene expression imputation across multiple brain regions provides insights into schizophrenia 
risk. Nat. Genet. 51, 659–674. https://doi.org/10.1038/s41588-019-0364-4 
Ikeda, M., Aleksic, B., Kinoshita, Y., Okochi, T., Kawashima, K., Kushima, I., Ito, Y., Nakamura, Y., Kishi, 
T., Okumura, T., Fukuo, Y., Williams, H.J., Hamshere, M.L., Ivanov, D., Inada, T., Suzuki, M., 
Hashimoto, R., Ujike, H., Takeda, M., Craddock, N., Kaibuchi, K., Owen, M.J., Ozaki, N., 
O Do o a , M.C., I ata, N., . Ge o e-Wide Association Study of Schizophrenia in a 
Japanese Population. Biol. Psychiatry 69, 472–478. 
https://doi.org/10.1016/j.biopsych.2010.07.010 
Iossifov, I., Ronemus, M., Levy, D., Wang, Z., Hakker, I., Rosenbaum, J., Yamrom, B., Lee, Y., Narzisi, 
G., Leotta, A., Kendall, J., Grabowska, E., Ma, B., Marks, S., Rodgers, L., Stepansky, A., Troge, J., 
Andrews, P., Bekritsky, M., Pradhan, K., Ghiban, E., Kramer, M., Parla, J., Demeter, R., Fulton, 
L.L., Fulton, R.S., Magrini, V.J., Ye, K., Darnell, J.C., Darnell, R.B., Mardis, E.R., Wilson, R.K., 
Schatz, M.C., McCombie, W.R., Wigler, M., 2012. De Novo Gene Disruptions in Children on the 
Autistic Spectrum. Neuron 74, 285–299. https://doi.org/10.1016/J.NEURON.2012.04.009 
Irish Schizophrenia Consortium and the Wellcome Trust Case Control Consortium 2, 2012. Genome-
Wide Association Study Implicates HLA-C*01:02 as a Risk Factor at the Major Histocompatibility 
Complex Locus in Schizophrenia. Biol. Psychiatry 72, 620–628. 
https://doi.org/10.1016/J.BIOPSYCH.2012.05.035 
Jiang, H., Qiao, F., Li, Z., Zhang, Y., Cheng, Y., Xu, X., Yu, L., 2015. Evaluating the association between 
CACNA1C rs1006737 and schizophrenia risk: A meta-analysis. Asia-Pacific Psychiatry 7, 260–
267. https://doi.org/10.1111/appy.12173 
Jones, H.J., Stergiakouli, E., Tansey, K.E., Hubbard, L., Heron, J., Cannon, M., Holmans, P., Lewis, G., 
Li de , D.E.J., Jo es, P.B., Da ey S ith, G., O Do o a , M.C., O e , M.J., Walters, J.T., )a it, 
S., 2016. Phenotypic Manifestation of Genetic Risk for Schizophrenia During Adolescence in the 
General Population. JAMA Psychiatry 73, 221. 
https://doi.org/10.1001/jamapsychiatry.2015.3058 
Keller, M.C., 2018. Evolutionary Perspectives on Genetic and Environmental Risk Factors for 
Psychiatric Disorders. Annu. Rev. Clin. Psychol. 14, 471–493. https://doi.org/10.1146/annurev-
clinpsy-050817-084854 
Kendall, K.M., Rees, E., Escott-Pri e, V., Ei o , M., Tho as, ‘., He itt, J., O Do o a , M.C., O e , 
M.J., Walters, J.T.R., Kirov, G., 2017. Cognitive Performance Among Carriers of Pathogenic Copy 
Number Variants: Analysis of 152,000 UK Biobank Subjects. Biol. Psychiatry 82, 103–110. 
https://doi.org/10.1016/J.BIOPSYCH.2016.08.014 
Khashan, A.S., Abel, K.M., McNamee, R., Pedersen, M.G., Webb, R.T., Baker, P.N., Kenny, L.C., 
Mortensen, P.B., 2008. Higher Risk of Offspring Schizophrenia Following Antenatal Maternal 
Exposure to Severe Adverse Life Events. Arch. Gen. Psychiatry 65, 146. 
https://doi.org/10.1001/archgenpsychiatry.2007.20 
Kirov, G., Pocklington, A.J., Holmans, P., Ivanov, D., Ikeda, M., Ruderfer, D., Moran, J., Chambert, K., 
Toncheva, D., Georgieva, L., Grozeva, D., Fjodorova, M., Wollerton, R., Rees, E., Nikolov, I., van 
de Lagemaat, L.N., Bayés, À., Fernandez, E., Olason, P.I., Böttcher, Y., Komiyama, N.H., Collins, 
M.O., Choudhary, J., Stefansson, K., Stefansson, H., Grant, S.G.N., Purcell, S., Sklar, P., 
O Do o a , M.C., O e , M.J., . De o o CNV a alysis i pli ates spe ifi  a or alities of 
postsynaptic signalling complexes in the pathogenesis of schizophrenia. Mol. Psychiatry 17, 
142–153. https://doi.org/10.1038/mp.2011.154 
Lam, M., Chen, C.-Y., Li, Z., Martin, A., Bryois, J., Ma, Xixian, Gaspar, H., Ikeda, M., Benyamin, B., 
Brown, B., Liu, R., Zhou, W., Huan, L., Kamatani, Y., Kim, S.-W., Kubo, M., Kusumawardhani, A., 
Liu, C.-M., Ma, H., Periyasamy, S., Takahashi, A., Wang, Q., Xu, Z., Yu, H., Zhu, F., Group, P.G.C.-
S.W., Consortium, I.S., (GREAT-CN), G.Re. on schizophreniA neTwork-C. and N., Chen, W., 
Faraone, S., Glatt, S., He, L., Hyman, S., Hwu, H.-G., Li, T., McCarroll, S., Neale, B., Sklar, P., 
Wildenauer, D., Yu, X., Zhang, D., Mowry, B., Lee, J., Holmans, P., Xu, S., Sullivan, P., Ripke, S., 
O Do o a , M., Daly, M., Qi , S., Sha , P., I ata, N., Ho g, K., Schwab, S., Yue, W., Tsuang, M., 
Liu, J., Ma, Xiancang, Kahn, R., Shi, Y., Huang, H., 2018. Comparative genetic architectures of 
schizophrenia in East Asian and European populations. bioRxiv 445874. 
https://doi.org/10.1101/445874 
Lee, J.J., Wedow, R., Okbay, A., Kong, E., Maghzian, O., Zacher, M., Nguyen-Viet, T.A., Bowers, P., 
Sidorenko, J., Karlsson Linnér, R., Fontana, M.A., Kundu, T., Lee, C., Li, H., Li, R., Royer, R., 
Timshel, P.N., Walters, R.K., Willoughby, E.A., Yengo, L., Alver, M., Bao, Y., Clark, D.W., Day, 
F.R., Furlotte, N.A., Joshi, P.K., Kemper, K.E., Kleinman, A., Langenberg, C., Mägi, R., Trampush, 
J.W., Verma, S.S., Wu, Y., Lam, M., Zhao, J.H., Zheng, Z., Boardman, J.D., Campbell, H., Freese, 
J., Harris, K.M., Hayward, C., Herd, P., Kumari, M., Lencz, T., Luan, J., Malhotra, A.K., Metspalu, 
A., Milani, L., Ong, K.K., Perry, J.R.B., Porteous, D.J., Ritchie, M.D., Smart, M.C., Smith, B.H., 
Tung, J.Y., Wareham, N.J., Wilson, J.F., Beauchamp, J.P., Conley, D.C., Esko, T., Lehrer, S.F., 
Magnusson, P.K.E., Oskarsson, S., Pers, T.H., Robinson, M.R., Thom, K., Watson, C., Chabris, 
C.F., Meyer, M.N., Laibson, D.I., Yang, J., Johannesson, M., Koellinger, P.D., Turley, P., Visscher, 
P.M., Benjamin, D.J., Cesarini, D., 2018. Gene discovery and polygenic prediction from a 
genome-wide association study of educational attainment in 1.1 million individuals. Nat. Genet. 
50, 1112–1121. https://doi.org/10.1038/s41588-018-0147-3 
Legge, S.., Dennison, C.., Pardiñas, A.F., Rees, E., Lynham, A.J., Hopkins, L., Bates, L., Kirov, G., Owen, 
M.J., O Do o a , M.C., Walters, J.T.‘., . Cli i al i di ators of treat e t-resistant 
schizophrenia. Br. J. Psychiatry. 
Lehner, T., 2012. The Genes in the Major Histocompatibility Complex as Risk Factors for 
Schizophrenia: De Omnibus Dubitandum. Biol. Psychiatry 72, 615–616. 
https://doi.org/10.1016/j.biopsych.2012.08.002 
Li, Z., Chen, J., Yu, H., He, L., Xu, Y., Zhang, D., Yi, Q., Li, C., Li, X., Shen, J., Song, Z., Ji, W., Wang, M., 
Zhou, J., Chen, B., Liu, Y., Wang, J., Wang, P., Yang, P., Wang, Q., Feng, G., Liu, B., Sun, W., Li, B., 
He, G., Li, Weidong, Wan, C., Xu, Q., Li, Wenjin, Wen, Z., Liu, K., Huang, F., Ji, J., Ripke, S., Yue, 
W., Sulli a , P.F., O Do o a , M.C., Shi, Y., . Ge o e-wide association analysis identifies 
30 new susceptibility loci for schizophrenia. Nat. Genet. 49, 1576–1583. 
https://doi.org/10.1038/ng.3973 
Lynham, A.J., Hubbard, L., Tansey, K.E., Hamshere, M.L., Legge, S.E., Owen, M.J., Jones, I.R., Walters, 
J.T.R.R., 2018. Examining cognition across the bipolar/schizophrenia diagnostic spectrum. J. 
Psychiatry Neurosci. 43, 245–253. 
Manolio, T.A., Collins, F.S., Cox, N.J., Goldstein, D.B., Hindorff, L.A., Hunter, D.J., McCarthy, M.I., 
Ramos, E.M., Cardon, L.R., Chakravarti, A., Cho, J.H., Guttmacher, A.E., Kong, A., Kruglyak, L., 
Mardis, E., Rotimi, C.N., Slatkin, M., Valle, D., Whittemore, A.S., Boehnke, M., Clark, A.G., 
Eichler, E.E., Gibson, G., Haines, J.L., Mackay, T.F.C., McCarroll, S.A., Visscher, P.M., 2009. 
Finding the missing heritability of complex diseases. Nature 461, 747–753. 
https://doi.org/10.1038/nature08494 
Martin, A.K., Mowry, B., 2016. Increased rare duplication burden genomewide in patients with 
treatment-resistant schizophrenia. Psychol. Med. 46, 469–476. 
https://doi.org/10.1017/S0033291715001701 
Martin, A.R., Gignoux, C.R., Walters, R.K., Wojcik, G.L., Neale, B.M., Gravel, S., Daly, M.J., 
Bustamante, C.D., Kenny, E.E., 2017. Human Demographic History Impacts Genetic Risk 
Prediction across Diverse Populations. Am. J. Hum. Genet. 100, 635–649. 
https://doi.org/10.1016/J.AJHG.2017.03.004 
Martin, A.R., Kanai, M., Kamatani, Y., Okada, Y., Neale, B.M., Daly, M.J., 2019. Clinical use of current 
polygenic risk scores may exacerbate health disparities. Nat. Genet. 51, 584–591. 
https://doi.org/10.1038/s41588-019-0379-x 
Mathieson, I., Munafò, M.R., Flint, J., 2012. Meta-analysis indicates that common variants at the 
DISC1 locus are not associated with schizophrenia. Mol. Psychiatry 17, 634–641. 
https://doi.org/10.1038/mp.2011.41 
Matzaraki, V., Kumar, V., Wijmenga, C., Zhernakova, A., 2017. The MHC locus and genetic 
susceptibility to autoimmune and infectious diseases. Genome Biol. 18, 76. 
https://doi.org/10.1186/s13059-017-1207-1 
Meier, S.M., Agerbo, E., Maier, R., Pedersen, C.B., Lang, M., Grove, J., Hollegaard, M. V, Demontis, 
D., Trabjerg, B.B., Hjorthøj, C., Ripke, S., Degenhardt, F., Nöthen, M.M., Rujescu, D., Maier, W., 
Werge, T., Mors, O., Hougaard, D.M., Børglum, A.D., Wray, N.R., Rietschel, M., Nordentoft, M., 
Mortensen, P.B., Mattheisen, M., Mattheisen, M., 2016. High loading of polygenic risk in cases 
with chronic schizophrenia. Mol. Psychiatry 21, 969–974. https://doi.org/10.1038/mp.2015.130 
Mistry, S., Harrison, J.R., Smith, D.J., Escott-Price, V., Zammit, S., 2018. The use of polygenic risk 
scores to identify phenotypes associated with genetic risk of schizophrenia: Systematic review. 
Schizophr. Res. 197, 2–8. https://doi.org/10.1016/J.SCHRES.2017.10.037 
Niarchou, M., Chawner, S.J.R.A., Doherty, J.L., Maillard, A.M., Jacquemont, S., Chung, W.K., Green-
Snyder, L., Bernier, R.A., Goin-Kochel, R.P., Hanson, E., Linden, D.E.J., Linden, S.C., Raymond, 
F.L., Skuse, D., Hall, J., Owen, M.J., Bree, M.B.M. van den, 2019. Psychiatric disorders in children 
with 16p11.2 deletion and duplication. Transl. Psychiatry 9, 8. https://doi.org/10.1038/s41398-
018-0339-8 
Nurnberger, J.I., Koller, D.L., Jung, J., Edenberg, H.J., Foroud, T., Guella, I., Vawter, M.P., Kelsoe, J.R., 
2014. Identification of Pathways for Bipolar Disorder. JAMA Psychiatry 71, 657. 
https://doi.org/10.1001/jamapsychiatry.2014.176 
O Do o a , M.C., Craddo k, N., Norto , N., Willia s, H., Peir e, T., Mosk i a, V., Nikolo , I., 
Hamshere, M., Carroll, L., Georgieva, L., Dwyer, S., Holmans, P., Marchini, J.L., Spencer, C.C.A., 
Howie, B., Leung, H.-T., Hartmann, A.M., Möller, H.-J., Morris, D.W., Shi, Y., Feng, G., Hoffmann, 
P., Propping, P., Vasilescu, C., Maier, W., Rietschel, M., Zammit, S., Schumacher, J., Quinn, E.M., 
Schulze, T.G., Williams, N.M., Giegling, I., Iwata, N., Ikeda, M., Darvasi, A., Shifman, S., He, L., 
Duan, J., Sanders, A.R., Levinson, D.F., Gejman, P. V, Cichon, S., Nöthen, M.M., Gill, M., Corvin, 
A., Rujescu, D., Kirov, G., Owen, M.J., Freedman, R., Amin, F., Black, D.W., Silverman, J.M., 
Byerley, W.F., Cloninger, C.R., Cichon, S., Nöthen, M.M., Gill, M., Corvin, A., Rujescu, D., Kirov, 
G., Owen, M.J., 2008. Identification of loci associated with schizophrenia by genome-wide 
association and follow-up. Nat. Genet. 40, 1053–1055. https://doi.org/10.1038/ng.201 
O Do o a , M.C., Owen, M.J., 2016. The implications of the shared genetics of psychiatric disorders. 
Nat. Med. 22, 1214–1219. https://doi.org/10.1038/nm.4196 
Owen, M.J., 2012. Implications of Genetic Findings for Understanding Schizophrenia. Schizophr. Bull. 
38, 904–907. https://doi.org/10.1093/schbul/sbs103 
Pardiñas, A.F., Holmans, P., Pocklington, A.J., Escott-Price, V., Ripke, S., Carrera, N., Legge, S.E., 
Bishop, S., Cameron, D., Hamshere, M.L., Han, J., Hubbard, L., Lynham, A., Mantripragada, K., 
Rees, E., MacCabe, J.H., McCarroll, S.A., Baune, B.T., Breen, G., Byrne, E.M., Dannlowski, U., 
Eley, T.C., Hayward, C., Martin, N.G., McIntosh, A.M., Plomin, R., Porteous, D.J., Wray, N.R., 
Caballero, A., Geschwind, D.H., Huckins, L.M., Ruderfer, D.M., Santiago, E., Sklar, P., Stahl, E.A., 
Won, H., Agerbo, E., Als, T.D., Andreassen, O.A., Bækvad-Hansen, M., Mortensen, P.B., 
Pedersen, C.B., Børglum, A.D., Bybjerg-Grauholm, J., Djurovic, S., Durmishi, N., Pedersen, M.G., 
Golimbet, V., Grove, J., Hougaard, D.M., Mattheisen, M., Molden, E., Mors, O., Nordentoft, M., 
Pejovic-Milovancevic, M., Sigurdsson, E., Silagadze, T., Hansen, C.S., Stefansson, K., Stefansson, 
H., Steinberg, S., Tosato, S., Werge, T., Collier, D.A., Rujescu, D., Kirov, G., Owen, M.J., 
O Do o a , M.C., Walters, J.T.R., 2018. Common schizophrenia alleles are enriched in 
mutation-intolerant genes and in regions under strong background selection. Nat. Genet. 50, 
381–389. https://doi.org/10.1038/s41588-018-0059-2 
Pocklington, A.J., Rees, E., Walters, J.T.R., Han, J., Kavanagh, D.H., Chambert, K.D., Holmans, P., 
Mora , J.L., M Carroll, S.A., Kiro , G., O Do o a , M.C., O e , M.J., . No el Fi di gs fro  
CNVs Implicate Inhibitory and Excitatory Signaling Complexes in Schizophrenia. Neuron 86, 
1203–14. https://doi.org/10.1016/j.neuron.2015.04.022 
Pouget, J.G., 2018. The Emerging Immunogenetic Architecture of Schizophrenia. Schizophr. Bull. 44, 
993–1004. https://doi.org/10.1093/schbul/sby038 
Psychiatric GWAS Consortium Bipolar Disorder Working Group., 2011. Large-scale genome-wide 
association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. Nat. 
Genet. 43, 977–983. https://doi.org/10.1038/ng.943 
Pur ell, S.M., Mora , J.L., Fro er, M., ‘uderfer, D., Solo ieff, N., ‘oussos, P., O Dushlai e, C., 
Chambert, K., Bergen, S.E., Kähler, A., Duncan, L., Stahl, E., Genovese, G., Fernández, E., Collins, 
M.O., Komiyama, N.H., Choudhary, J.S., Magnusson, P.K.E., Banks, E., Shakir, K., Garimella, K., 
Fennell, T., DePristo, M., Grant, S.G.N., Haggarty, S.J., Gabriel, S., Scolnick, E.M., Lander, E.S., 
Hultman, C.M., Sullivan, P.F., McCarroll, S.A., Sklar, P., 2014. A polygenic burden of rare 
disruptive mutations in schizophrenia. Nature 506, 185–190. 
https://doi.org/10.1038/nature12975 
Rees, E., Walters, J.T.R., Georgieva, L., Isles, A.R., Chambert, K.D., Richards, A.L., Mahoney-Davies, G., 
Legge, S.E., Mora , J.L., M Carroll, S.A., O Do o a , M.C., O e , M.J., Kiro , G., . A alysis 
of copy number variations at 15 schizophrenia-associated loci. Br. J. Psychiatry 204, 108–114. 
https://doi.org/10.1192/bjp.bp.113.131052 
‘ipke, S., O Dushlai e, C., Cha ert, K., Mora , J.L., Kähler, A.K., Akteri , S., Berge , S.E., Colli s, 
A.L., Crowley, J.J., Fromer, M., Kim, Y., Lee, S.H., Magnusson, P.K.E., Sanchez, N., Stahl, E.A., 
Williams, S., Wray, N.R., Xia, K., Bettella, F., Borglum, A.D., Bulik-Sullivan, B.K., Cormican, P., 
Craddock, N., de Leeuw, C., Durmishi, N., Gill, M., Golimbet, V., Hamshere, M.L., Holmans, P., 
Hougaard, D.M., Kendler, K.S., Lin, K., Morris, D.W., Mors, O., Mortensen, P.B., Neale, B.M., 
O Neill, F.A., O e , M.J., Milo a e i , M.P., Posthu a, D., Po ell, J., ‘i hards, A.L., ‘iley, B.P., 
Ruderfer, D., Rujescu, D., Sigurdsson, E., Silagadze, T., Smit, A.B., Stefansson, H., Steinberg, S., 
Su isaari, J., Tosato, S., Verhage, M., Walters, J.T., Bra o , E., Cor i , A.P., O Do o a , M.C., 
Stefansson, K., Scolnick, E., Purcell, S., McCarroll, S.A., Sklar, P., Hultman, C.M., Sullivan, P.F., 
Schwab, S.G., Wildenauer, D.B., Dudbridge, F., Holmans, P., Shi, J., Albus, M., Alexander, M., 
Campion, D., Cohen, D., Dikeos, D., Duan, J., Eichhammer, P., Godard, S., Hansen, M., Lerer, 
F.B., Liang, K.-Y., Maier, W., Mallet, J., Nert ey, D.A., Nestadt, G., Norto , N., O Neill, F.A., 
Papadimitriou, G.N., Ribble, R., Sanders, A.R., Silverman, J.M., Walsh, D., Williams, N.M., 
Wormley, B., Consortium, P.E.I., Arranz, M.J., Bakker, S., Bender, S., Bramon, E., Collier, D., 
Crespo-Facorro, B., Hall, J., Iyegbe, C., Jablensky, A., Kahn, R.S., Kalaydjieva, L., Lawrie, S., Lewis, 
C.M., Lin, K., Linszen, D.H., Mata, I., McIntosh, A., Murray, R.M., Ophoff, R.A., Powell, J., 
Rujescu, D., Os, J. Van, Walshe, M., Weisbrod, M., Wiersma, D., 2, W.T.C.C.C., Bramon, E., 
Cor i , A.P., O Do o a , M.C., Stefa sso , K., S ol i k, E., Purcell, S., McCarroll, S.A., Sklar, P., 
Hultman, C.M., Sullivan, P.F., 2013. Genome-wide association analysis identifies 13 new risk loci 
for schizophrenia. Nat. Genet. 45, 1150–1159. https://doi.org/10.1038/ng.2742 
Risch, N., Zhang, H., 1995. Extreme discordant sib pairs for mapping quantitative trait loci in humans. 
Science (80-. ). 268, 1584–1589. https://doi.org/10.1126/SCIENCE.7777857 
Ruderfer, D.M., Ripke, S., McQuillin, A., Boocock, J., Stahl, E.A., Pavlides, J.M.W., Mullins, N., 
Charney, A.W., Ori, A.P.S., Loohuis, L.M.O., Domenici, E., Di Florio, A., Papiol, S., Kalman, J.L., 
Trubetskoy, V., Adolfsson, R., Agartz, I., Agerbo, E., Akil, H., Albani, D., Albus, M., Alda, M., 
Alexander, M., Alliey-Rodriguez, N., Als, T.D., Amin, F., Anjorin, A., Arranz, M.J., Awasthi, S., 
Bacanu, S.A., Badner, J.A., Baekvad-Hansen, M., Bakker, S., Band, G., Barchas, J.D., Barroso, I., 
Bass, N., Bauer, M., Baune, B.T., Begemann, M., Bellenguez, C., Belliveau, R.A., Bellivier, F., 
Bender, S., Bene, J., Bergen, S.E., Berrettini, W.H., Bevilacqua, E., Biernacka, J.M., Bigdeli, T.B., 
Black, D.W., Blackburn, H., Blackwell, J.M., Blackwood, D.H.R., Pedersen, C.B., Boehnke, M., 
Boks, M., Borglum, A.D., Bramon, E., Breen, G., Brown, M.A., Bruggeman, R., Buccola, N.G., 
Buckner, R.L., Budde, M., Bulik-Sullivan, B., Bumpstead, S.J., Bunney, W., Burmeister, M., 
Buxbaum, J.D., Bybjerg-Grauholm, J., Byerley, W., Cahn, W., Cai, G., Cairns, M.J., Campion, D., 
Cantor, R.M., Carr, V.J., Carrera, N., Casas, J.P., Casas, M., Catts, S. V., Cervantes, P., Chambert, 
K.D., Chan, R.C.K., Chen, E.Y.H., Chen, R.Y.L., Cheng, W., Cheung, E.F.C., Chong, S.A., Clarke, T.-
K., Cloninger, C.R., Cohen, D., Cohen, N., Coleman, J.R.I., Collier, D.A., Cormican, P., Coryell, W., 
Craddock, N., Craig, D.W., Crespo-Facorro, B., Crowley, J.J., Cruceanu, C., Curtis, D., Czerski, 
P.M., Dale, A.M., Daly, M.J., Dannlowski, U., Darvasi, A., Davidson, M., Davis, K.L., de Leeuw, 
C.A., Degenhardt, F., Del Favero, J., DeLisi, L.E., Deloukas, P., Demontis, D., DePaulo, J.R., di 
Forti, M., Dikeos, D., Dinan, T., Djurovic, S., Dobbyn, A.L., Donnelly, P., Donohoe, G., Drapeau, 
E., Dronov, S., Duan, J., Dudbridge, F., Duncanson, A., Edenberg, H., Edkins, S., Ehrenreich, H., 
Eichhammer, P., Elvsashagen, T., Eriksson, J., Escott-Price, V., Esko, T., Essioux, L., Etain, B., Fan, 
C.C., Farh, K.-H., Farrell, M.S., Flickinger, M., Foroud, T.M., Forty, L., Frank, J., Franke, L., Fraser, 
C., Freedman, R., Freeman, C., Freimer, N.B., Friedman, J.I., Fromer, M., Frye, M.A., Fullerton, 
J.M., Gade, K., Garnham, J., Gaspar, H.A., Gejman, P. V., Genovese, G., Georgieva, L., 
Giambartolomei, C., Giannoulatou, E., Giegling, I., Gill, M., Gillman, M., Pedersen, M.G., Giusti-
Rodriguez, P., Godard, S., Goes, F., Goldstein, J.I., Gopal, S., Gordon, S.D., Gordon-Smith, K., 
Gratten, J., Gray, E., Green, E.K., Green, M.J., Greenwood, T.A., Grigoroiu-Serbanescu, M., 
Grove, J., Guan, W., Gurling, H., Parra, J.G., Gwilliam, R., de Haan, L., Hall, J., Hall, M.-H., 
Hammer, C., Hammond, N., Hamshere, M.L., Hansen, M., Hansen, T., Haroutunian, V., 
Hartmann, A.M., Hauser, J., Hautzinger, M., Heilbronner, U., Hellenthal, G., Henskens, F.A., 
Herms, S., Hipolito, M., Hirschhorn, J.N., Hoffmann, P., Hollegaard, M. V., Hougaard, D.M., 
Huang, H., Huckins, L., Hultman, C.M., Hunt, S.E., Ikeda, M., Iwata, N., Iyegbe, C., Jablensky, A. 
V., Jamain, S., Jankowski, J., Jayakumar, A., Joa, I., Jones, I., Jones, L.A., Jonsson, E.G., Julia, A., 
Jureus, A., Kahler, A.K., Kahn, R.S., Kalaydjieva, L., Kandaswamy, R., Karachanak-Yankova, S., 
Karjalainen, J., Karlsson, R., Kavanagh, D., Keller, M.C., Kelly, B.J., Kelsoe, J., Kennedy, J.L., 
Khrunin, A., Kim, Y., Kirov, G., Kittel-Schneider, S., Klovins, J., Knight, J., Knott, S. V., Knowles, 
J.A., Kogevinas, M., Konte, B., Kravariti, E., Kucinskas, V., Kucinskiene, Z.A., Kupka, R., Kuzelova-
Ptackova, H., Landen, M., Langford, C., Laurent, C., Lawrence, J., Lawrie, S., Lawson, W.B., 
Leber, M., Leboyer, M., Lee, P.H., Keong, J.L.C., Legge, S.E., Lencz, T., Lerer, B., Levinson, D.F., 
Levy, S.E., Lewis, C.M., Li, J.Z., Li, M., Li, Q.S., Li, T., Liang, K.-Y., Liddle, J., Lieberman, J., 
Limborska, S., Lin, K., Linszen, D.H., Lissowska, J., Liu, C., Liu, J., Lonnqvist, J., Loughland, C.M., 
Lubinski, J., Lucae, S., Macek, M., MacIntyre, D.J., Magnusson, P.K.E., Maher, B.S., Mahon, P.B., 
Maier, W., Malhotra, A.K., Mallet, J., Malt, U.F., Markus, H.S., Marsal, S., Martin, N.G., Mata, I., 
Mathew, C.G., Mattheisen, M., Mattingsdal, M., Mayoral, F., McCann, O.T., McCarley, R.W., 
McCarroll, S.A., McCarthy, M.I., McDonald, C., McElroy, S.L., McGuffin, P., McInnis, M.G., 
McIntosh, A.M., McKay, J.D., McMahon, F.J., Medeiros, H., Medland, S.E., Meier, S., Meijer, 
C.J., Melegh, B., Melle, I., Meng, F., Mesholam-Gately, R.I., Metspalu, A., Michie, P.T., Milani, L., 
Milanova, V., Mitchell, P.B., Mokrab, Y., Montgomery, G.W., Moran, J.L., Morken, G., Morris, 
D.W., Mors, O., Mortensen, P.B., Mowry, B.J., Mühleisen, T.W., Müller-Myhsok, B., Murphy, 
K.C., Murray, R.M., Myers, R.M., Myin-Germeys, I., Neale, B.M., Nelis, M., Nenadic, I., Nertney, 
D.A., Nestadt, G., Nicodemus, K.K., Nievergelt, C.M., Nikitina-Zake, L., Nimgaonkar, V., 
Nise au , L., Norde toft, M., Nordi , A., Nöthe , M.M., N ulia, E.A., O Callagha , E., 
O Do o a , C., O Dushlai e, C., O Neill, F.A., Oedegaard, K.J., Oh, S.-Y., Olincy, A., Olsen, L., 
Oruc, L., Van Os, J., Owen, M.J., Paciga, S.A., Palmer, C.N.A., Palotie, A., Pantelis, C., 
Papadimitriou, G.N., Parkhomenko, E., Pato, C., Pato, M.T., Paunio, T., Pearson, R., Perkins, 
D.O., Perlis, R.H., Perry, A., Pers, T.H., Petryshen, T.L., Pfennig, A., Picchioni, M., Pietilainen, O., 
Pimm, J., Pirinen, M., Plomin, R., Pocklington, A.J., Posthuma, D., Potash, J.B., Potter, S.C., 
Powell, J., Price, A., Pulver, A.E., Purcell, S.M., Quested, D., Ramos-Quiroga, J.A., Rasmussen, 
H.B., Rautanen, A., Ravindrarajah, R., Regeer, E.J., Reichenberg, A., Reif, A., Reimers, M.A., 
Ribases, M., Rice, J.P., Richards, A.L., Ricketts, M., Riley, B.P., Rivas, F., Rivera, M., Roffman, J.L., 
Rouleau, G.A., Roussos, P., Rujescu, D., Salomaa, V., Sanchez-Mora, C., Sanders, A.R., Sawcer, 
S.J., Schall, U., Schatzberg, A.F., Scheftner, W.A., Schofield, P.R., Schork, N.J., Schwab, S.G., 
Scolnick, E.M., Scott, L.J., Scott, R.J., Seidman, L.J., Serretti, A., Sham, P.C., Weickert, C.S., 
Shehktman, T., Shi, J., Shilling, P.D., Sigurdsson, E., Silverman, J.M., Sim, K., Slaney, C., 
Slominsky, P., Smeland, O.B., Smoller, J.W., So, H.-C., Sobell, J.L., Soderman, E., Hansen, C.S., 
Spencer, C.C.A., Spijker, A.T., St Clair, D., Stefansson, H., Stefansson, K., Steinberg, S., 
Stogmann, E., Stordal, E., Strange, A., Straub, R.E., Strauss, J.S., Streit, F., Strengman, E., 
Strohmaier, J., Stroup, T.S., Su, Z., Subramaniam, M., Suvisaari, J., Svrakic, D.M., Szatkiewicz, 
J.P., Szelinger, S., Tashakkori-Ghanbaria, A., Thirumalai, S., Thompson, R.C., Thorgeirsson, T.E., 
Toncheva, D., Tooney, P.A., Tosato, S., Toulopoulou, T., Trembath, R.C., Treutlein, J., 
Trubetskoy, V., Turecki, G., Vaaler, A.E., Vedder, H., Vieta, E., Vincent, J., Visscher, P.M., 
Viswanathan, A.C., Vukcevic, D., Waddington, J., Waller, M., Walsh, D., Walshe, M., Walters, 
J.T.R., Wang, D., Wang, Q., Wang, W., Wang, Y., Watson, S.J., Webb, B.T., Weickert, T.W., 
Weinberger, D.R., Weisbrod, M., Weiser, M., Werge, T., Weston, P., Whittaker, P., Widaa, S., 
Wiersma, D., Wildenauer, D.B., Williams, N.M., Williams, S., Witt, S.H., Wolen, A.R., Wong, 
E.H.M., Wood, N.W., Wormley, B.K., Wu, J.Q., Xi, S., Xu, W., Young, A.H., Zai, C.C., Zandi, P., 
Zhang, P., Zheng, X., Zimprich, F., Zollner, S., Corvin, A., Fanous, A.H., Cichon, S., Rietschel, M., 
Gershon, E.S., Schulze, T.G., Cuellar-Barboza, A.B., Forstner, A.J., Holmans, P.A., Nurnberger, 
J.I., A dreasse , O.A., Lee, S.H., O Do o a , M.C., Sulli a , P.F., Ophoff, ‘.A., Wray, N.‘., Sklar, 
P., Kendler, K.S., 2018. Genomic Dissection of Bipolar Disorder and Schizophrenia, Including 28 
Subphenotypes. Cell 173, 1705-1715.e16. https://doi.org/10.1016/J.CELL.2018.05.046 
Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014. Biological insights from 
108 schizophrenia-associated genetic loci. Nature 511, 421–427. 
https://doi.org/10.1038/nature13595 
Sekar, A., Bialas, A.R., de Rivera, H., Davis, A., Hammond, T.R., Kamitaki, N., Tooley, K., Presumey, J., 
Baum, M., Van Doren, V., Genovese, G., Rose, S.A., Handsaker, R.E., Schizophrenia Working 
Group of the Psychiatric Genomics Consortium, S.W.G. of the P.G., Daly, M.J., Carroll, M.C., 
Stevens, B., McCarroll, S.A., 2016. Schizophrenia risk from complex variation of complement 
component 4. Nature 530, 177–83. https://doi.org/10.1038/nature16549 
Shafee, R., Nanda, P., Padmanabhan, J.L., Tandon, N., Alliey-Rodriguez, N., Kalapurakkel, S., Weiner, 
D.J., Gur, R.E., Keefe, R.S.E., Hill, S.K., Bishop, J.R., Clementz, B.A., Tamminga, C.A., Gershon, 
E.S., Pearlson, G.D., Keshavan, M.S., Sweeney, J.A., McCarroll, S.A., Robinson, E.B., 2018. 
Polygenic risk for schizophrenia and measured domains of cognition in individuals with 
psychosis and controls. Transl. Psychiatry 8, 78. https://doi.org/10.1038/s41398-018-0124-8 
Shi, J., Le i so , D.F., Dua , J., Sa ders, A.‘., )he g, Y., Pe er, I., Dud ridge, F., Hol a s, P.A., 
Whittemore, A.S., Mowry, B.J., Olincy, A., Amin, F., Cloninger, C.R., Silverman, J.M., Buccola, 
N.G., Byerley, W.F., Black, D.W., Crowe, R.R., Oksenberg, J.R., Mirel, D.B., Kendler, K.S., 
Freedman, R., Gejman, P. V., 2009. Common variants on chromosome 6p22.1 are associated 
with schizophrenia. Nature 460, 753–757. https://doi.org/10.1038/nature08192 
Spain, S.L., Barrett, J.C., 2015. Strategies for fine-mapping complex traits. Hum. Mol. Genet. 24, 
R111–R119. https://doi.org/10.1093/hmg/ddv260 
Stefansson, H., Ophoff, R.A., Steinberg, S., Andreassen, O.A., Cichon, S., Rujescu, D., Werge, T., 
Pietiläinen, O.P.H., Mors, O., Mortensen, P.B., Sigurdsson, E., Gustafsson, O., Nyegaard, M., 
Tuulio-Henriksson, A., Ingason, A., Hansen, T., Suvisaari, J., Lonnqvist, J., Paunio, T., Børglum, 
A.D., Hartmann, A., Fink-Jensen, A., Nordentoft, M., Hougaard, D., Norgaard-Pedersen, B., 
Böttcher, Y., Olesen, J., Breuer, R., Möller, H.-J., Giegling, I., Rasmussen, H.B., Timm, S., 
Mattheisen, M., Bitter, I., Réthelyi, J.M., Magnusdottir, B.B., Sigmundsson, T., Olason, P., 
Masson, G., Gulcher, J.R., Haraldsson, M., Fossdal, R., Thorgeirsson, T.E., Thorsteinsdottir, U., 
Ruggeri, M., Tosato, S., Franke, B., Strengman, E., Kiemeney, L.A., Melle, I., Djurovic, S., 
Abramova, L., Kaleda, V., Sanjuan, J., de Frutos, R., Bramon, E., Vassos, E., Fraser, G., Ettinger, 
U., Picchioni, M., Walker, N., Toulopoulou, T., Need, A.C., Ge, D., Lim Yoon, J., Shianna, K. V., 
Freimer, N.B., Cantor, R.M., Murray, R., Kong, A., Golimbet, V., Carracedo, A., Arango, C., 
Costas, J., Jönsson, E.G., Terenius, L., Agartz, I., Petursson, H., Nöthen, M.M., Rietschel, M., 
Matthews, P.M., Muglia, P., Peltonen, L., St Clair, D., Goldstein, D.B., Stefansson, K., Collier, 
D.A., Petursson, H., Nöthen, M.M., Rietschel, M., Matthews, P.M., Muglia, P., Peltonen, L., Clair, 
D.S., Goldstei , D.B., Stefa sso , K., Collier, D.A., G‘OUP†, †Ge eti  ‘isk a d Out o e i  
Psychosis, Melle, I., Djurovic, S., Abramova, L., Kaleda, V., Sanjuan, J., de Frutos, R., Bramon, E., 
Vassos, E., Fraser, G., Ettinger, U., Picchioni, M., Walker, N., Toulopoulou, T., Need, A.C., Ge, D., 
Lim Yoon, J., Shianna, K. V., Freimer, N.B., Cantor, R.M., Murray, R., Kong, A., Golimbet, V., 
Carracedo, A., Arango, C., Costas, J., Jönsson, E.G., Terenius, L., Agartz, I., Petursson, H., 
Nöthen, M.M., Rietschel, M., Matthews, P.M., Muglia, P., Peltonen, L., St Clair, D., Goldstein, 
D.B., Stefansson, K., Collier, D.A., Kahn, R.S., Linszen, D.H., van Os, J., Wiersma, D., Bruggeman, 
R., Cahn, W., de Haan, L., Krabbendam, L., Myin-Germeys, I., 2009. Common variants conferring 
risk of schizophrenia. Nature 460, 744–747. https://doi.org/10.1038/nature08186 
Steinberg, J., Webber, C., 2013. The Roles of FMRP-Regulated Genes in Autism Spectrum Disorder: 
Single- and Multiple-Hit Genetic Etiologies. Am. J. Hum. Genet. 93, 825–839. 
https://doi.org/10.1016/J.AJHG.2013.09.013 
Sullivan, P.F., 2013. Questions about DISC1 as a genetic risk factor for schizophrenia. Mol. Psychiatry 
18, 1050–1052. https://doi.org/10.1038/mp.2012.182 
Sullivan, P.F., Agrawal, A., Bulik, C.M., Andreassen, O.A., Børglum, A.D., Breen, G., Cichon, S., 
Edenberg, H.J., Faraone, S. V., Gelernter, J., Mathews, C.A., Nievergelt, C.M., Smoller, J.W., 
O Do o a , M.C., Co sortiu ,  for the P.G., . Psy hiatri  Ge o i s: A  Update a d a  
Agenda. Am. J. Psychiatry 175, 15–27. https://doi.org/10.1176/appi.ajp.2017.17030283 
Sulli a , P.F., Daly, M.J., O Do o a , M., 2012. Genetic architectures of psychiatric disorders: the 
emerging picture and its implications. Nat. Rev. Genet. 13, 537–551. 
https://doi.org/10.1038/nrg3240 
Sullivan, P.F., Lin, D., Tzeng, J.-Y., van den Oord, E., Perkins, D., Stroup, T.S., Wagner, M., Lee, S., 
Wright, F.A., Zou, F., Liu, W., Downing, A.M., Lieberman, J., Close, S.L., 2008. Genomewide 
association for schizophrenia in the CATIE study: results of stage 1. Mol. Psychiatry 13, 570–
584. https://doi.org/10.1038/mp.2008.25 
The Brainstorm Consortium, 2018. Analysis of shared heritability in common disorders of the brain. 
Science 360, eaap8757. https://doi.org/10.1126/science.aap8757 
The International Schizophrenia Consortium, 2009. Common polygenic variation contributes to risk 
of schizophrenia and bipolar disorder. Nature 460, 748. https://doi.org/10.1038/nature08185 
The Network and Pathway Analysis Subgroup of the Psychiatric Genomics Consortium, 2015. 
Psychiatric genome-wide association study analyses implicate neuronal, immune and histone 
pathways. Nat. Neurosci. 18, 199–209. https://doi.org/10.1038/nn.3922 
The Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium, 2011. Genome-
wide association study identifies five new schizophrenia loci. Nat. Genet. 43, 969–976. 
https://doi.org/10.1038/ng.940 
Torkamani, A., Wineinger, N.E., Topol, E.J., 2018. The personal and clinical utility of polygenic risk 
scores. Nat. Rev. Genet. 19, 581–590. https://doi.org/10.1038/s41576-018-0018-x 
van Dijk, E.L., Auger, H., Jaszczyszyn, Y., Thermes, C., 2014. Ten years of next-generation sequencing 
technology. Trends Genet. 30, 418–426. https://doi.org/10.1016/J.TIG.2014.07.001 
Vassos, E., Di Forti, M., Cole a , J., Iyeg e, C., Prata, D., Euesde , J., O ‘eilly, P., Curtis, C., Kolliakou, 
A., Patel, H., Newhouse, S., Traylor, M., Ajnakina, O., Mondelli, V., Marques, T.R., Gardner-
Sood, P., Aitchison, K.J., Powell, J., Atakan, Z., Greenwood, K.E., Smith, S., Ismail, K., Pariante, 
C., Gaughran, F., Dazzan, P., Markus, H.S., David, A.S., Lewis, C.M., Murray, R.M., Breen, G., 
2017. An Examination of Polygenic Score Risk Prediction in Individuals With First-Episode 
Psychosis. Biol. Psychiatry 81, 470–477. https://doi.org/10.1016/J.BIOPSYCH.2016.06.028 
Wald, N.J., Hackshaw, A.K., Frost, C.D., 1999. When can a risk factor be used as a worthwhile 
screening test? BMJ 319, 1562–5. 
Wang, X., Chua, H.-X., Chen, P., Ong, R.T.-H., Sim, X., Zhang, W., Takeuchi, F., Liu, X., Khor, C.-C., Tay, 
W.-T., Cheng, C.-Y., Suo, C., Liu, J., Aung, T., Chia, K.-S., Kooner, J.S., Chambers, J.C., Wong, T.-Y., 
Tai, E.-S., Kato, N., Teo, Y.-Y., 2013. Comparing methods for performing trans-ethnic meta-
analysis of genome-wide association studies. Hum. Mol. Genet. 22, 2303–2311. 
https://doi.org/10.1093/hmg/ddt064 
Wassef, A., Baker, J., Kochan, L., 2003. GABA and Schizophrenia: A Review of Basic Science and 
Clinical Studies. J. Clin. Psychopharmacol. 23, 601–640. 
Wimberley, T., Gasse, C., Meier, S.M., Agerbo, E., MacCabe, J.H., Horsdal, H.T., 2017. Polygenic Risk 
Score for Schizophrenia and Treatment-Resistant Schizophrenia. Schizophr. Bull. 43, 1064–
1069. https://doi.org/10.1093/schbul/sbx007 
Wu, C., DeWan, A., Hoh, J., Wang, Z., 2011. A Comparison of Association Methods Correcting for 
Population Stratification in Case-Control Studies. Ann. Hum. Genet. 75, 418–427. 
https://doi.org/10.1111/j.1469-1809.2010.00639.x 
Yu, H., Yan, H., Li, J., Li, Z., Zhang, X., Ma, Y., Mei, L., Liu, C., Cai, L., Wang, Q., Zhang, F., Iwata, N., 
Ikeda, M., Wang, L., Lu, T., Li, M., Xu, H., Wu, X., Liu, B., Yang, J., Li, K., Lv, L., Ma, X., Wang, C., 
Li, L., Yang, F., Jiang, T., Shi, Y., Li, T., Zhang, D., Yue, W., Yue, W., 2017. Common variants on 
2p16.1, 6p22.1 and 10q24.32 are associated with schizophrenia in Han Chinese population. 
Mol. Psychiatry 22, 954–960. https://doi.org/10.1038/mp.2016.212 
Yue, W.-H., Wang, H.-F., Sun, L.-D., Tang, F.-L., Liu, Z.-H., Zhang, H.-X., Li, W.-Q., Zhang, Y.-L., Zhang, 
Y., Ma, C.-C., Du, B., Wang, L.-F., Ren, Y.-Q., Yang, Y.-F., Hu, X.-F., Wang, Yi, Deng, W., Tan, L.-
W., Tan, Y.-L., Chen, Q., Xu, G.-M., Yang, G.-G., Zuo, X., Yan, H., Ruan, Y.-Y., Lu, T.-L., Han, X., 
Ma, X.-H., Wang, Yan, Cai, L.-W., Jin, C., Zhang, H.-Y., Yan, J., Mi, W.-F., Yin, X.-Y., Ma, W.-B., Liu, 
Q., Kang, L., Sun, W., Pan, C.-Y., Shuang, M., Yang, F.-D., Wang, C.-Y., Yang, J.-L., Li, K.-Q., Ma, X., 
Li, L.-J., Yu, X., Li, Q.-Z., Huang, X., Lv, L.-X., Li, T., Zhao, G.-P., Huang, W., Zhang, X.-J., Zhang, D., 
2011. Genome-wide association study identifies a susceptibility locus for schizophrenia in Han 
Chinese at 11p11.2. Nat. Genet. 43, 1228–31. https://doi.org/10.1038/ng.979 
Yue, W., Yu, X., Zhang, D., 2017. Progress in genome-wide association studies of schizophrenia in 
Han Chinese populations. npj Schizophr. 3, 24. https://doi.org/10.1038/s41537-017-0029-1 
Zondervan, K.T., Cardon, L.R., 2004. Erratum: The complex interplay among factors that influence 




Figure 1: PRS-based stratification of the CLOZUK sample (Pardiñas et al., 2018), showing proportion of 
schizophrenia cases within each percentile and the OR conferred by comparing it with the 1st 
percentile. PRS p-value threshold used was 0.05, as it produced the largest AUC and r2 for case 
discrimination. P‘S ere al ulated usi g I depe de t PGC  as a trai i g set ,  ases a d ,  
o trols   a d CLO)UK  as a target set ,  ases a d ,  o trols), as detailed in Pardiñas et 
al. (2018). 
 
